Puma Common Stock Total Equity from 2010 to 2026

PBYI Stock  USD 6.32  0.25  3.81%   
Puma Biotechnology's Common Stock Total Equity is decreasing with slightly volatile movements from year to year. Common Stock Total Equity is predicted to flatten to 4,275. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2007-09-30
Previous Quarter
K
Current Value
K
Quarterly Volatility
64.3 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Puma Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Puma Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 15 M, Other Operating Expenses of 179.8 M or Operating Income of 37.4 M, as well as many indicators such as Price To Sales Ratio of 0.61, Dividend Yield of 0.0 or PTB Ratio of 1.76. Puma financial statements analysis is a perfect complement when working with Puma Biotechnology Valuation or Volatility modules.
  
Build AI portfolio with Puma Stock
Check out the analysis of Puma Biotechnology Correlation against competitors.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

Latest Puma Biotechnology's Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Puma Biotechnology over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Puma Biotechnology's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Puma Common Stock Total Equity Regression Statistics

Arithmetic Mean21,281
Geometric Mean4,865
Coefficient Of Variation337.52
Mean Deviation32,790
Median4,000
Standard Deviation71,829
Sample Variance5.2B
Range298K
R-Value(0.40)
Mean Square Error4.6B
R-Squared0.16
Significance0.11
Slope(5,675)
Total Sum of Squares82.6B

Puma Common Stock Total Equity History

2026 4275.0
2025 4500.0
2022 5000.0
2016 4000.0
2012 3000.0
2011 2004.0
2010300 K

About Puma Biotechnology Financial Statements

Investors use fundamental indicators, such as Puma Biotechnology's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Puma Biotechnology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Common Stock Total Equity4.5 K4.3 K

Currently Active Assets on Macroaxis

When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:
Check out the analysis of Puma Biotechnology Correlation against competitors.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.58)
Earnings Share
0.74
Revenue Per Share
4.267
Quarterly Revenue Growth
(0.32)
Return On Assets
0.099
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.